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ABSTRACT
Objective To evaluate the relationship between health-
related quality of life (HR-QoL) and both physical and
psychiatric factors in a large, international, multicentre
cohort of patients with isolated dystonia, the Dystonia
Coalition.
Methods Natural history data from 603 patients with
isolated dystonia (median age 57 years (IQR: 48 to 64
years), 67.0% women) were prospectively acquired
and analysed. HR-QoL (RAND 36-Item Health Survey),
severity of depressive symptoms, generalised anxiety
(Hospital Anxiety and Depression Scale) and social
anxiety (Liebowitz Social Anxiety Scale) were assessed.
Dystonia severity (Burke-Fahn-Marsden Dystonia Rating
Scale) and dystonic tremor were examined. Statistical
predictors of HR-QoL were calculated using saturated
path analysis.
Results Reduced HR-QoL was strongly associated with
the degree of depressive symptoms and generalised
and social anxiety (8/8 RAND 36 subscales, p≤0.001).
Increased dystonia severity was associated with worse
physical functioning, physical and emotional role
functioning and social functioning (all p≤0.001). The
presence of tremor correlated with worse physical
functioning and pain (all p≤0.006). Younger age was
associated with reduced emotional well-being and
vitality (all p≤0.006). There were no HR-QoL differences
between sexes.
Conclusion HR-QoL in isolated dystonia is strongly
associated with psychiatric and physical features.
While current standard of care focus on motor aspects
of dystonia, comprehensive care should address both
physical and mental aspects of health.

INTRODUCTION
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Health-
related quality of life (HR-
QoL) is
reduced in patients with dystonia compared with
population-based samples.1–4 HR-QoL in dystonia
is not only determined by motor symptoms (MS)
including dystonia severity and dystonic tremor
but also by non-motor symptoms (NMS), that is,
depression, anxiety, social phobia, low self-esteem
and pain.3 5 NMS are frequent in dystonia in
comparison to population-
based samples, which
have an annual prevalence of 7% for depression,6 1% to 6% for generalised anxiety disorder
(GAD)7–9 and 2% to 8% for social anxiety disorder

(SAD).9 10 The point prevalence in dystonia is 16%
to 48% for depression, 20% to 50% for GAD and
40% for SAD.3 5 11–14 The relationship between MS
and NMS is poorly understood, that is, to which
extent NMS are secondary due to MS or a result of
impaired neuronal processing.15
Previous studies in dystonia aimed to reveal the
relationship of HR-QoL with MS and NMS.15–17
Their significance, however, has been limited due
to relatively small sample sizes and methodological
differences, for example, between self-
evaluation
of dystonia severity versus rating of dystonia by
an experienced investigator.15–17 Thus, no systematic analysis of the influence of MS and NMS
severity on HR-QoL has yet been performed in a
comprehensive dystonia cohort. Here, we analysed
data from the Dystonia Coalition cohort, a large
prospectively investigated and international sample
of patients with isolated dystonia, and hypothesised that psychiatric manifestations have a higher
impact on HR-
QoL than dystonia severity and
tremor. Mental health of patients with dystonia
and its overall burden on HR-QoL may not be well
addressed since dystonia treatment mainly focusses
on the motor aspects of the disease.

METHODS
Participants

The analysis included participants’ data from baseline assessment of the Natural History Project of
the Dystonia Coalition clinical database enrolled
between 12 January 2011 and 3 November 2017
across 36 clinical sites (USA, Canada, Australia,
Germany, France and Italy). Additional Dystonia
Coalition investigators that contributed subjects to
the study are listed in online supplemental file. The
Dystonia Coalition is a multicentre study of patients
with isolated dystonia, aged 18 years and older, and
the Natural History Project includes patients with
dystonia onset no more than 5 years prior to study
enrolment (https://www.rarediseasesnetwork.org/
cms/dystonia).
Participants answered a standardised questionnaire and were clinically examined using a standardised protocol. Patients with dystonia with
botulinum toxin (BoNT) treatment were enrolled
when symptoms returned. This usually meant
they were enrolled 3 months after treatment, but
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never less than 2 months after treatment. Exclusion criteria
were secondary and combined dystonia and medical/neurological conditions confounding diagnoses or precluding a complete
assessment. For the current study a small group of patients with
a confirmed mutation in a dystonia-related gene were excluded
(n=12) as certain monogenic forms, for example, SGCE-related
dystonia, exhibit a specific neuropsychiatric profile and are thus
accompanied by a high burden of NMS.18
Classification of dystonia referring to body distribution
was conducted according to Albanese et al.19 Type of dystonia
was divided into focal, segmental, multifocal and generalised
dystonia. Focal dystonia was further divided into blepharospasm,
oromandibular/lingual, laryngeal, cervical and limb dystonia.

Liebowitz Social Anxiety Scale

The self-reported Liebowitz Social Anxiety Scale (LSAS) is a
24-item scale divided into two subscales assessing fear/anxiety
concerning performance and pertaining to social situations as
well as avoidance behaviour.22 The 24 items of the two subscales
are rated on a Likert scale from 0 to 3 yielding a maximum sum
score of 144. The presence of social anxiety was indicated by a
standard scale cut-off >30.

Examination protocol and rating

HR-QoL and NMS were evaluated by generic, validated and
widely used rating scales (RAND 36-Item Health Survey, Hospital
Anxiety and Depression Scale, Liebowitz Social Anxiety Scale)
to allow for comparison with other dystonia and movement
disorder studies.20–22

Standardised examination of all patients included evaluation of
eyes, mouth, tongue, neck, arms, hands, legs and feet and the
examination of speech, voice, swallowing, handwriting, standing
and walking.24 A movement disorder neurologist evaluated
dystonia severity across different body regions using the validated Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS).25
Tremor was assessed by observing all body regions for the
occurrence of tremor regardless of its amplitude, frequency or
regularity. The BFMDRS evaluates provoking (scale 0 to 4) and
severity factors (scale 0 to 4) of nine different body parts (eyes,
mouth, speech/swallowing, neck, right arm, left arm, right leg,
left leg, trunk). For each body part, provoking factor, severity
factor and a weight factor (0.5 or 1) were multiplied yielding
score ranges from 0 to 120, with higher scores indicating more
severe dystonia.

Dystonia Coalition Questionnaire

Statistical analysis

Standard protocol approvals and patient consents

All participants gave written informed consent for study participation prior to study enrolment.

Questionnaire and rating scales

Demographic and clinical data included sex, age, affected body
regions, the presence of other movement disorders including
tremor, age at onset, disease duration, medical treatment for
dystonia, medical history and mutations in dystonia-
related
genes.

RAND 36-Item Health Survey

HR-QoL was evaluated using the RAND 36-Item Health Survey
1.0. The RAND 36 is a generic quality of life questionnaire to
measure physical and mental well-being, relies on patient self-
reporting and was developed in the Medical Outcome Study.20 It
contains 36 questions representing the following eight subscales:
general health, physical functioning, role limitations due to
physical health problems, pain, energy/fatigue, emotional well-
being, role limitations due to emotional problems and social
functioning. The questions are rated on a Likert scale with up
to six response options and seven questions are answered with
yes or no. Original response categories are recoded to values of
a 0% to 100% range and the items of each of the eight subscales
are averaged. A high score represents a better health state. The
RAND 36-Item Health Survey 1.0 and the 36-Item Short Form
Survey (SF-36) include the same items, while the scoring algorithm is different regarding the general health and pain scales.23
The scoring algorithm of the RAND 36-Item Health Survey 1.0
was used in this study.

Hospital Anxiety and Depression Scale

Severity of generalised anxiety and depressive symptoms was
assessed by the self-reported Hospital Anxiety and Depression
Scale (HADS) V.4.21 Each of the two subscales (HADS-A and
HADS-D) contain seven questions rated on a 4-point scale (0 to
3), each subscale yielding score ranging from 0 to 21. Standard
scale cut-offs indicated the presence of depression and anxiety
(HADS-A >7 and HADS-D >7).
2

To analyse the relationship between MS and NMS with HR-QoL,
simultaneously estimated bivariate correlations were obtained
from a saturated path analysis performed in MPlus V.7.4.26 The
eight subscales of the RAND 36-Item Health Survey, the three
NMS scores (HADS-D, HADS-A and LSAS), and the two MS
factors (BFMDRS and tremor (yes/no)) were entered into the
model, as well as age and sex to control for their effects. The
Full Information Maximum Likelihood statistical procedure was
used for replacement of missing values in the path analysis that
was undertaken. Bonferroni-corrected alphas were calculated to
adjust for multiple comparisons (simultaneous correlations), and
p values ≤0.006 were considered significant.
Differences regarding the severity of NMS between patients
with and without antidepressants were assessed using t-tests for
independent samples. All tests of significance were two-sided.
Bonferroni-corrected alphas ≤0.017 were considered significant.

Data availability

Anonymised data (study protocol and statistical analysis) will be
shared by request from any qualified investigator. Data will be
available for 10 years.

RESULTS

Out of 615 participants, 12 were excluded due to secondary or
combined dystonia or a confirmed mutation in a dystonia-related
gene. Of the remaining 603 patients with isolated dystonia, 1.5%
of data points were missing.
The majority of patients were women (67.0%, 404/603). The
median age at baseline examination was 57 years (IQR: 48 to 64
years), and the median age at dystonia onset 54 years (IQR: 45
to 61 years). Table 1 displays mean BFMDRS scores, the ratio
of patients with tremor, mean total scores of RAND 36-Item
Health Survey, HADS-D, HADS-A and LSAS as well as the ratio
of patients with symptoms of a depression (HADS-D >7), GAD
(HADS-A >7) and SAD (LSAS >30). In detail, symptoms of
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Table 1

Clinical data of the study cohort
HR-QoL

Depression

Generalised
anxiety

Social anxiety

BFMDRS

Tremor

63.6±21.8

21.5%
(127/591)
4.6±4.0

36.7%
(217/591)
6.4±4.2

44.3%
(262/591)
32.1±26.0

6.7±5.0

43%
(259/603)

 Focal (n=373)

66.3±21.8

20.0 %
(73/365)
4.4±4.0

37.3 %
(136/365)
6.4±4.1

41.5%
(152/366)
30.9±25.4

4.4±2.4

44.0 %
(164/373)

 Segmental (n=171)

58.0±21.0

24.6%
(41/167)
5.4±4.1

36.5 %
(61/167)
6.7±4.2

55.1%
(92/167)
36.8±26.7

9.8±5.3

39.8%
(68/171)

 Multifocal (n=49)

64.4±20.9

20.4%
(10/49)
3.9±3.3

30.6%
(15/49)
5.3±4.2

30.6%
(15/49)
25.9±24.7

9.5±4.4

42.9%
(21/49)

 
Generalised (n=10)

58.1±24.9

30%
(3/10)
5.0±4.4

50%
(5/10)
7.3±5.3

33.3%
(3/9)
29.4±34.3

21.4±9.4

60%
(6/10)

 Blepharospasm (n=41)

70.8±20.3

19.5%
(8/41)
4.3±4.2

24.4%
(10/41)
5.3±4.1

19.5%
(8/41)
24.2±25.8

4.6±2.3

14.6 %
(6/41)

 Oromandibular/lingual (n=22)

67.7±19.9

18.2%
(4/22)
4.7±4.0

22.7%
(5/22)
5.5±3.5

36.4%
(8/22)
27.9±20.0

3.8±3.0

27.3%
(6/22)

 Laryngeal (n=30)

77.1±15.6

13.3%
(4/30)
3.1±3.1

46.7%
(14/30)
7.8±4.3

66.7%
(20/30)
40.7±23.6

3.1±1.8

33.3%
(10/30)

 Cervical (n=227)

62.3±22.6

23.2%
(51/220)
4.7±4.1

41.8%
(92/220)
6.8±4.2

45.0%
(99/220)
33.1±26.8

4.7±2.3

57.3%
(130/227)

 Limb (n=53)

73.1±18.9

11.5%
(6/52)
3.4±3.3

28.8%
(15/52)
5.4±3.3

32.1%
(17/53)
22.8±17.8

3.8±2.5

22.6%
(12/53)

All (n=603)

Main groups of dystonia

Subgroups of focal dystonia

HR-QoL and BFMDRS: Mean RAND 36-Item Health Survey total scores (range 0% to 100%) and mean BFMDRS scores with SD of all patients and per type of dystonia.
Depression, GAD and SAD: Percentage and numbers of patients with symptoms of depression (HADS-D > 7), GAD (HADS-A > 7), SAD (LSAS > 30) and mean HADS-D, mean
HADS-A and mean LSAS scores with SD of all patients and per type of dystonia.
Tremor: Percentage and numbers of patients with dystonic tremor of all patients and per type of dystonia.
BFMDRS, Burke-Fahn-Marsden Dystonia Rating Scale; GAD, generalised anxiety disorder; HADS, Hospital Anxiety and Depression Scale; HR-QoL, health-related quality of life;
LSAS, Liebowitz Social Anxiety Scale; SAD, social anxiety disorder.

depression were found in 22%, symptoms of GAD in 37% and
SAD in 44% of patients.
With regard to therapy, 68.0% (410/603) were treated with
BoNT, 39.5% (238/603) with oral anti-dystonic drugs (anticholinergics, benzodiazepines, non-
benzo hypnotics, dopaminergics, antidopaminergics and muscle relaxants) and 19.1% with
antidepressants. The group of patients with antidepressants
(depression: 6.3±4.3 vs 4.2±3.8 (M±SD), t(589) = −5.1,
p<0.000; GAD: 8.2±4.2 vs 6.0±4.0 (M±SD), t(589) = −5.3,
p<0.000; SAD: 38.6±30.0 vs 30.6±24.7 (M±SD), t(589) =
−3.0, p=0.003) exhibited higher depression and anxiety scores.
None of the patients had deep brain stimulation, whereas 0.8%
of patients had previously received other surgical treatment for
dystonia (myectomy for blepharospasm or spasmodic dysphonia
(n=3), selective denervation for cervical dystonia (n=2)).

HR-QoL of all eight subscales related to more severe depressive
symptoms, GAD and SAD (all p≤0.001). Depressive symptoms
presented with highest (−0.47 up to −0.72) and social anxiety
with lowest estimates (−0.23 up to −0.42). Higher dystonia
severity was associated with lower physical functioning, physical and emotional role functioning and social functioning (all
p≤0.001), and the presence of tremor was associated with lower
HR-QoL regarding physical functioning and pain (all p≤0.006).
Both dystonia severity and tremor presented low estimates
(−0.09 up to −0.24). Younger age was associated with reduced
emotional well-being and vitality (all p≤0.006, estimates 0.13 to
0.15). Sex was not associated with any differences in HR-QoL
subscales.

DISCUSSION
Influence of MS and NMS on HR-QoL in dystonia

The results of the path analysis with numerical estimates as
indicators of the strength of the relationships between the eight
HR-QoL subscales (RAND 36-Item Health Survey) and dystonia
severity (BFMDRS), tremor, severity of depressive symptoms
(HADS-D), GAD (HADS-A) and SAD (LSAS), as well as age at
examination and sex are displayed in table 2 and figure 1. Lower
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Symptoms of depression, GAD and SAD are related to worse
HR-
QoL in patients with dystonia in the large international
Dystonia Coalition cohort. We found an additional association
of HR-QoL with dystonia severity, tremor and age at examination. Twenty per cent of our patients were treated with antidepressants. The degree of underlying depressive symptoms and
anxiety may thus have been underestimated.
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Table 2

Simultaneously estimated bivariate correlations obtained from a saturated path analysis

Health-related quality of life
subscale

Dystonia severity

Tremor

Depression

Generalised
anxiety

Social anxiety

Age

Sex

General health

−0.09
(−0.17 to −0.01)

−0.05
(−0.13 to 0.03)

−0.50***
(−0.57 to −0.44)

−0.40***
(−0.47 to −0.33)

−0.31***
(−0.39 to −0.22)

0.07
(−0.01 to 0.15)

−0.04
(−0.12 to 0.04)

Physical functioning

−0.14***
(−0.22 to −0.06)

−0.14***
(−0.22 to −0.06)

−0.47***
(−0.54 to −0.4)

−0.27***
(−0.35 to −0.18)

−0.27***
(−0.36 to −0.18)

−0.07
(−0.15 to 0.01)

−0.07
(−0.15 to 0.002)

Physical role functioning

−0.24***
(−0.32 to −0.16)

−0.01
(−0.09 to 0.07)

−0.49***
(−0.55 to −0.43)

−0.35***
(−0.42 to −0.28)

−0.26***
(−0.34 to −0.2)

0.08
(0.003 to 0.16)

−0.06
(−0.14 to 0.02)

Pain

−0.10
(−0.19 to −0.001)

−0.11**
(−0.19 to −0.03)

−0.52***
(−0.58 to −0.45)

−0.38***
(−0.46 to −0.31)

−0.23***
(−0.32 to −0.14)

0.11
(0.03 to 0.2)

−0.07
(−0.15 to 0.01)

Energy/fatigue

−0.09
(−0.17 to −0.01)

−0.09
(−0.18 to −0.01)

−0.66***
(−0.71 to −0.61)

−0.45***
(−0.51 to −0.38)

−0.34***
(−0.41 to −0.27)

0.13**
(0.05 to 0.21)

−0.05
(−0.13 to 0.03)

Emotional well-being

−0.11
(−0.2 to −0.02)

−0.002
(−0.08 to 0.08)

−0.72***
(−0.76 to −0.67)

−0.68***
(−0.72 to −0.63)

−0.41***
(−0.49 to −0.33)

0.15***
(0.07 to 0.22)

0.01
(−0.07 to 0.09)

Emotional role functioning

−0.17***
(−0.26 to −0.09)

0.02
(−0.06 to 0.1)

−0.49***
(−0.56 to −0.42)

−0.42***
(−0.48 to −0.35)

−0.32***
(−0.4 to −0.24)

0.11
(0.03 to 0.19)

0.01
(−0.07 to 0.09)

Social functioning

−0.23***
(−0.32 to −0.15)

−0.004
(−0.09 to 0.08)

−0.67***
(−0.72 to −0.62)

−0.44***
(−0.5 to −0.37)

−0.42***
(−0.5 to −0.35)

0.10
(0.02 to 0.18)

0.05
(−0.03 to 0.14)

Path analysis: Numerical estimates and 95% CIs as indicators of the strength of the relationships between the eight HR-QoL subscales (RAND 36-Item Health Survey) and dystonia severity
(BFMDRS), tremor, severity of depression (HADS-D), severity of generalised anxiety (HADS-A), severity of social anxiety (LSAS), age and sex in 603 patients with dystonia.
** Bonferroni corrected alpha ≤ 0.006; ***p ≤ 0.001
BFMDRS, Burke-Fahn-Marsden Dystonia Rating Scale; HADS, Hospital Anxiety and Depression Scale; HR-QoL, health-related quality of life; LSAS, Liebowitz Social Anxiety Scale.

Our results are in keeping with previous studies in smaller
samples of patients with dystonia, which have already indicated that depression, GAD, low self-
esteem, embarrassment and acceptance of illness are important determinants of
HR-QoL.3 16 17 27 28Motor severity was, however, not as strongly
associated with HR-QoL in our study. The weaker association
with motor severity may be due to the fact that we used the
BFMDRS to assess dystonia severity which is a validated25 and
commonly used rating scale but it may not be sensitive enough
for focal dystonias. In keeping with this notion, most patients
had focal or segmental dystonia in our sample whereas generalised (10/603) and multifocal (49/603) dystonias were less
common. Other studies have also found a stronger relationship of QoL with NMS than with MS but this may again be

attributable to the heterogeneity of dystonia subtypes in different
cohorts and especially in those with smaller sample sizes and the
use of different rating scales (BFMDRS, TWSTRS, Tsui score,
UDRS).3 11 27 Furthermore, the examination of patients under
BoNT treatment at different time intervals limits the comparability of results. Of note, almost 70% of our patients were
treated with BoNT about 3 months prior to the examination,
indicating that dystonia severity may have been potentially
higher in some patients without long-term BoNT therapy29 and
may have resulted in stronger associations with lower HR-QoL.
Thus, it is conceivable that the impact of MS severity in our
and previous studies may be lessened by the availability and
ongoing utilisation of effective treatments as BoNT and deepbrain stimulation with positive long-term effects on HR-QoL,3 30

Figure 1 Simultaneously estimated bivariate correlations obtained from a saturated path analysis. Stylised illustration to demonstrate the strength of the
relationships between the eight HR-QoL subscales (RAND 36-Item Health Survey) and dystonia severity (BFMDRS), tremor, severity of depression (HADS-D),
severity of generalised anxiety (HADS-A), severity of social anxiety (LSAS) in 603 patients with dystonia. BFMDRS, Burke-Fahn-Marsden Dystonia Rating
Scale; HADS, Hospital Anxiety and Depression Scale; HR-QoL,health-related quality of life; LSAS, Liebowitz SocialAnxiety Scale.
4
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as compared with the potentially less uniform implementation
of treatments for the NMS. MS and MS-related pain should of
course be treated to improve and stabilise HR-QoL.31–35
Dystonic tremor is a frequent clinical sign in dystonia36 and
tremor is a source of reduced QoL in other tremor types.37 The
impact of dystonic tremor on HR-QoL in patients with dystonia
has previously not been sufficiently addressed. We found that
dystonic tremor was negatively associated with physical functioning and pain-related QoL. Although patients were evaluated as symptoms returned after BoNT treatment, a sustained
improvement in patients with long-term BoNT therapy cannot
be excluded. Therefore, investigations of patients who are
BoNT-naive may reveal even stronger associations. Our results
implicate the importance of treating dystonic tremor to improve
HR-QoL.
based studies illustrate age-
dependent and sex-
Population-
dependent prevalence of psychiatric conditions with a decrease
in people >50 years of age and women being more anxious.6–8
Controlling our analysis for age and sex, HR-QoL in patients
with dystonia did not differ between men and women, while
younger age in dystonia was associated with reduced emotional
well-being and vitality.
The question of whether NMS are a primary phenomenon
of the disease or a secondary response to physical impairment
remains unanswered.15 In dystonia as well as in Parkinson’s
disease the most potent predictors of HR-QoL appear to be
depression and anxiety.38 39 An increased risk of recurrent major
depressive episodes in manifesting and non-manifesting TOR1A
mutation carriers argues for a primary phenomenon,40 while
higher depression and anxiety scores in symptomatic but not in
asymptomatic SCGE carriers may argue for this to be a secondary
epiphenomenon with the limitation that in most SGCE carriers
the mutated allele will be silenced.41 Recent reports of familial
coaggregation of psychiatric comorbidities in dystonia and an
impaired theory of mind in cervical dystonia support shared
genetic factors.42 43 High prevalences of social anxiety in dystonia
and QoL predictors as low self-
esteem, self-
deprecation and
educational level in cervical dystonia16 point towards an impact
of MS on HR-QoL although for most dystonias there may be a
bidirectional and dynamic relationship between MS and NMS.15
Our study has certain limitations: The size of the cohort allows
for drawing meaningful conclusions, even while controlling
for important confounders, such as sex and age. Nevertheless
further factors such as educational level, marital and socioeconomic status may significantly influence HR-QoL and were not
assessed to guarantee statistical power.
A considerable proportion of patients were treated with oral
anti-dystonic drugs and/or antidepressants. Their influence on
NMS was not controlled for because the mechanism of action
strongly varies across drug classes and some patients received
medication from more than one drug class and with different
dosages. Given the different drug targets and the contradictory or independent mechanisms (eg, dopaminergics vs anti-
dopaminergics or anti-
dystonic vs anti-
depressive effects) as
well as the co-medication in several patients we refrained from
a combined analysis. One of the inclusion criteria was disease
duration less than 5 years, which prevented the assessment of
later disease stages. Another limitation of our study is that only
carriers of known mutations in dystonia-
related genes were
excluded but that no systematic screening was performed.
Furthermore, new genes may not have yet been identified at
the time point of the study, for example, VPS16 which was very
recently described in the context of dominantly inherited isolated
dystonia.44 The rationale to exclude patients with a monogenic
Junker J, et al. J Neurol Neurosurg Psychiatry 2021;0:1–7. doi:10.1136/jnnp-2020-325193

background was to account for a potential confounder as they
may present with a distinct neuropsychiatric profile and a
different burden of NMS. The mutation frequency is, however,
very low in isolated dystonia cases whereas the likelihood to
identify causative mutations is considerably higher in combined
or complex dystonias as previously shown in a large dystonia
sample where exome sequencing was performed.45 46 Further,
mutations in dystonia-related genes are enriched in generalised
or multifocal dystonia although it can be very rarely found in
patients with focal dystonias. As most patients in our sample
suffered from focal dystonia (62%) we thus assume that the
number of unidentified mutations will be relatively low. The
BFMDRS is a validated25 and commonly used rating scale for
dystonia but it may not be sensitive enough for focal dystonias.
Furthermore, dystonic tremor is an important clinical feature
that is not well reflected in currently used clinical scales. Accordingly, the qualitative assessment in this study (tremor yes/no)
is no longer appropriate to account for the specific features of
dystonic tremor including distribution in different body regions,
frequency, amplitude, regularity in frequency and amplitude and
alleviating or provoking manoeuvres. Another prerequisite is the
sensitivity of a clinical rating scale to change, for example, due
to treatment. This is reflected by a recent paper showing that
the diagnosis of dystonic tremor is still problematic because of
different opinions on its very definition even across experts.47
HR-QoL in isolated dystonia is strongly associated especially
with NMS as well as less related to MS, while standard therapy
regimens only concentrate on the physical symptoms. Comprehensive care of patients with dystonia should address both physical and mental health and aim to improve acceptance of the
disease and coping strategies.
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